Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 6/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.33 |
| ▸ | GPR4 | P46093 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.30 |
| ▸ | VCP | P55072 | 1/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206922 | 0.93 | BCHE (0.37) | BCHEACHEBACE1MAP2K2MAP2K1 | |
| SCHEMBL6230497 | 0.93 | KCNH2 (0.38) | BCHEACHEBACE1MAP2K2MAP2K1 | |
| SCHEMBL6404616 | 0.92 | BCHE (0.37) | BCHEACHEBACE1MAP2K2MAP2K1 | |
| SCHEMBL6208052 | 0.92 | HRH3 (0.34) | BCHEACHEBACE1VCP | |
| SCHEMBL6206805 | 0.91 | BCHE (0.39) | BCHEACHEBACE1 | |
| SCHEMBL6208348 | 0.88 | EEF2K (0.37) | BCHEACHEBACE1KDM4E | |
| SCHEMBL6205424 | 0.88 | ACHE (0.56) | BCHEACHEBACE1NPC1 | |
| SCHEMBL6207402 | 0.85 | AVPR1A (0.33) | BCHEACHEBACE1VCP | |
| SCHEMBL6403567 | 0.85 | BCHE (0.43) | BCHEACHEBACE1KDM4E | |
| SCHEMBL6207041 | 0.84 | KDM4E (0.47) | KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | BCHE 3693/4885ACHE 2974/4885BACE1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.